Archive for category: BioScience Managers

 Seven patients with serious, life-threatening infections, not responding to antibiotics, were treated with AB-SA01 or AB-PA01, with six patients, 86%, achieving treatment success  Treatment was well tolerated in all patients, with over 500 doses administered intravenously or inhalation  AmpliPhi expects to continue its expanded access clinical strategy in 2018, review data with the FDA […]

Posted on 01/12/2017 THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE EU MARKET ABUSE REGULATION (596/2014). UPON THE PUBLICATION OF THE ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN. Destiny Pharma plc (“Destiny Pharma” or “the Company”) […]

Six patients with life-threatening S. aureus or P. aeruginosa infections treated to date with AB-SA01 or AB-PA01 under expanded access in the U.S. and Australia  Second clinical institution to treat patients with AB-SA01 or AB-PA01 under expanded access is now operational  First-in-human intravenous dosing of AB-SA01 as part of expanded access treatment of a patient […]

London, UK and Melbourne, Australia, 30 October 2017 – Leading healthcare investment specialist BioScience Managers Limited (BioScience Managers), has announced the expansion of its team with the addition of three new directors with broad sector and geographic experience – Dr Michael Perry as a Director, Dennis Purcell as a Director and Senior Expert Advisor, and […]

13 December 2016 Joint media release with the Hon. Sussan Ley MP, Minister for Health and Aged Care. The Turnbull Government is today launching the $500 million Biomedical Translation Fund, established under the government’s National Innovation and Science Agenda, which will help take Australian biomedical discoveries out of the laboratory and to the patient. Three […]